For Humanigen Inc. [HGEN], Analyst sees a drop to $2. What next?

Related

Humanigen Inc. [NASDAQ: HGEN] traded at a low on 07/25/22, posting a -4.57 loss after which it closed the day’ session at $0.41. The company report on July 12, 2022 that Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases’ (NIAID) ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients. The trial did not achieve statistical significance on the primary endpoint, which was defined as the proportion of patients with baseline CRP<150 mg/L and age<85 years, alive and without mechanical ventilation through Day 29. The data also showed a non-significant trend toward a reduction in mortality in the overall patient population [HR 0.72]. There were no new safety signals attributed to lenzilumab in the ACTIV-5/BET-B study. "We are grateful for the constructive collaboration with NIH/NIAID; while the ACTIV-5/BET-B study showed signs of a clinical effect, the benefit demonstrated was not able to confirm the positive results we saw in our Phase 3 LIVE-AIR study," said Cameron Durrant, Chairman and Chief Executive Officer, Humanigen. "In order to prove the therapeutic benefits of immunomodulators, platform studies comprising thousands of patients have been necessary. With the continued resurgence of COVID-19, further exploration of variant agnostic treatments to improve outcomes in hospitalized COVID-19 patients should be a priority.". The results of the trading session contributed to over 12413492 shares changing hands. Over the past one week, the price volatility of Humanigen Inc. stands at 5.50% while the volatility over the past one month is 15.67%. The market cap for HGEN stock reached $31.09 million, with 65.59 million shares outstanding and 56.39 million shares in the current float. Compared to the average trading volume of 5.11M shares, HGEN reached a trading volume of 12413492 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Humanigen Inc. [HGEN]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HGEN shares is $3.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HGEN stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for Humanigen Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 13, 2022. The new note on the price target was released on July 13, 2022, representing the official price target for Humanigen Inc. stock. Previously, the target price had yet another drop from $30 to $2, while Cantor Fitzgerald kept a Neutral rating on HGEN stock.

The Average True Range (ATR) for Humanigen Inc. is set at 0.27, with the Price to Sales ratio for HGEN stock in the period of the last 12 months amounting to 7.58.

How has HGEN stock performed recently?

Humanigen Inc. [HGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.35. With this latest performance, HGEN shares dropped by -83.07% in over the last four-week period, additionally sinking by -83.74% over the last 6 months – not to mention a drop of -97.47% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HGEN stock in for the last two-week period is set at 29.56, with the RSI for the last a single of trading hit 24.93, and the three-weeks RSI is set at 32.82 for Humanigen Inc. [HGEN]. The present Moving Average for the last 50 days of trading for this stock 1.9062, while it was recorded at 0.4471 for the last single week of trading, and 3.3828 for the last 200 days.

Humanigen Inc. [HGEN]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Humanigen Inc. [HGEN] shares currently have an operating margin of -6474.88. Humanigen Inc.’s Net Margin is presently recorded at -6582.73.

Return on Equity for this stock declined to -2,165.43, with Return on Assets sitting at -339.62.

Humanigen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.00.

Earnings analysis for Humanigen Inc. [HGEN]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HGEN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Humanigen Inc. go to 12.50%.

Insider trade positions for Humanigen Inc. [HGEN]

There are presently around $12 million, or 40.60% of HGEN stock, in the hands of institutional investors. The top three institutional holders of HGEN stocks are: VALIANT CAPITAL MANAGEMENT, L.P. with ownership of 6,888,607, which is approximately 0% of the company’s market cap and around 20.17% of the total institutional ownership; MURCHINSON LTD., holding 5,250,000 shares of the stock with an approximate value of $2.17 million in HGEN stocks shares; and BLACKROCK INC., currently with $1.39 million in HGEN stock with ownership of nearly 0.694% of the company’s market capitalization.

Positions in Humanigen Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 36 institutional holders increased their position in Humanigen Inc. [NASDAQ:HGEN] by around 3,344,648 shares. Additionally, 47 investors decreased positions by around 4,508,401 shares, while 19 investors held positions by with 20,654,782 shares. The mentioned changes placed institutional holdings at 28,507,831 shares, according to the latest SEC report filing. HGEN stock had 12 new institutional investments in for a total of 1,145,971 shares, while 20 institutional investors sold positions of 2,786,456 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]